• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by VALNEVA

    < Previous 1 2 3 4 Next >
    News headline image
    Valneva to Further Consolidate its Operations in France
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva to Participate at U.S. and European Investor Conferences in June
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
    From VALNEVA
    Via GlobeNewswire
    News headline image
    Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
    From VALNEVA
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.